Kayentis Chooses SFR Business Team for its "Machine to Machine" Roaming in Close to 250 Countries
Grenoble, 1st Septembre 2015 – Kayentis, French software provider specialized in solutions for clinical pharmaceutical trials, has just chosen SFR Business Team for its M2M roaming in close to 250 countries.
Kayentis has been a leading name in solutions for clinical trials for 10 years. 18 months ago, in addition to its emblematic digital pen device, the company launched a solution enabling patient data to be entered by tablet.
In order to implement its solutions in the international market, Kayentis wished to approach a major player in the telecoms sector and thus chose SFR Business Team. The partnership agreement between the two companies authorises M2M roaming in close to 250 countries.
This solution guarantees permanent connectivity between the clinic investigation centres, where the data is collected, the Kayentis database servers and the portal provided for its customers.
It has already been implemented in more than 40 countries, via two eCOA projects (eClinical Outcome Assessment) for phase III clinical studies, linked with one of the five largest pharmaceutical laboratories in the world.
Working with SFR Business Team has enabled Kayentis to lean on one of the leading names in MtoM solutions worldwide and strengthen the brand’s ambitious plans for development.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
